Nanotechnology Now - Press Release: "Endomagnetics Raises Additional Funding and Opens Cambridge Office"

Home > Press > Endomagnetics Raises Additional Funding and Opens Cambridge Office

Abstract:
Endomagnetics, the company which is using advanced magnetic technology to extend the availability of an important cancer staging procedure, has raised additional funding, taking the sum raised in the last few months to Ł1.8 million. The Company has also announced a move to Cambridge as it expands its operations.

Endomagnetics Raises Additional Funding and Opens Cambridge Office

Cambridge, UK | Posted on November 11th, 2011

Endomagnetics is a spin out from University College London (UCL), and is developing advanced magnetic sensors originally developed at UCL and at the University of Houston. The move to Cambridge reflects the company's rapid progress towards commercialisation of its first product. SentiMag® is an ultrasensitive hand-held probe capable of tracking the position of an associated magnetic tracer: Sienna+™, that helps to identify critical lymph nodes in support of cancer staging.

The system is now becoming available to clinicians to replace the radioactive isotopes currently used. Not only is the Endomagnetics system simpler and cheaper than the ‘gamma probe' technique currently used, but it provides a better experience for patients, surgeons and hospitals alike.

The additional investment has been provided by New Wave Ventures alongside internal investors, as an extension to the recent funding round that raised Ł1.2m in August.

"We are excited about the progress which Endomagnetics is making in the development of this important technique, and in the potential for its adoption around the world", said Tim Bullock, Chief Executive of New Wave Ventures. "Presently, only a small minority of people have access to the best standard of care techniques which magnetic sensing facilitates."

Speaking from the company's new headquarters on Cambridge Science Park, Endomagnetics CEO Dr Eric Mayes agreed: "We are delighted to be expanding our operations to Cambridge, close to so many other excellent technology companies and management talent. We expect to make full use of this as we expand."

Next month, Endomagnetics will be demonstrating SentiMag to surgeons and oncologists at the Breast Cancer Symposium in San Antonio, Texas, and anticipates another enthusiastic reception from clinicians attending.

####

About Endomagnetics
Endomagnetics was founded to solve cancer staging and healthcare challenges through the application of advanced magnetic sensing technology and nanotechnology. Endomagnetics is developing a portfolio of medical device products based on a patented ability to detect magnetic materials in the human body with exceptional sensitivity. The technology was originally developed at University College London and the University of Houston.

The company’s first product, the SentiMag®, is an ultrasensitive hand-held probe for detecting a magnetic tracer called Sienna+™ to help identify critical lymph nodes in support of cancer staging. Cambridge-based Endomagnetics is in the process of delivering its technology to global markets. For more information please visit www.endomagnetics.com.

About New Wave Ventures

New Wave Ventures LLP was formed as a vehicle for the personal business investments of its founders, Paul Newey and Tim Bullock. New Wave has no external investors or investment committee and addresses each investment opportunity with an open mind - aiming to achieve the most satisfactory structure for all parties. New Wave’s preference is to invest in high quality management teams with a strongly differentiated product and the potential to make a significant impact on markets with global scale.

For more information please visit www.nwventures.co.uk

For more information, please click here

Contacts:
Editorial contact:
Terry Nicklin
KeynotePR Ltd
Tel: +44 (0)7923 540695

Company contact:
Dr Eric Mayes
CEO
Endomagnetics Ltd
Tel: +44 (0)1223 437131

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: